Bioxcel Therapeutics (BTAIQ) AI Stock Analysis

Bioxcel Therapeutics

(Other OTC:BTAIQ)

Select Model

Rating:38Underperform

Price Target:$0.01▼(-7.69% Downside)

Action:reiterated

Date:10/31/26

The score is driven primarily by very weak financial performance (large losses, negative equity, and ongoing cash burn) and a highly negative corporate event backdrop (Chapter 11, asset sale, and transition to liquidation). Technicals also reflect a strong downtrend, and valuation provides little support given persistent losses and no dividend.

Positive Factors

AI-enabled drug discoveryAn AI-enabled discovery model gives the company a defined scientific strategy focused on neuroscience and immuno-oncology. Its emphasis on unmet medical needs could support valuable therapies if candidates advance, although the current business is no longer operating normally.

Negative Factors

Chapter 11 and liquidationChapter 11, the sale of substantially all neuroscience assets, executive- team termination, and the planned transition to BX Liquidation represent a fundamental loss of operating continuity. This sharply reduces the remaining business platform and creates severe uncertainty for shareholders.

Bioxcel Therapeutics (BTAIQ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $406.97K
Dividend Yield: ―
Average Volume (3M): 5.82M
Price to Earnings (P/E): -0.0
Beta (1Y): 2.48
Revenue Growth: -14.52%
EPS Growth: 66.63%
Country: US
Employees: 29
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Bioxcel Therapeutics Business Overview & Revenue Model

Company Description

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United Stat...

Bioxcel Therapeutics Financial Statement Overview

Summary

Financials are severely stressed: very small TTM revenue (~$0.7M), large net loss (~$70.9M), negative equity (~-$115.5M), and heavy cash burn (TTM operating/free cash flow ~-$50.9M). While losses and burn have improved versus prior years, the company remains far from break-even and highly dependent on external funding.

Income Statement

12Very Negative

Balance Sheet

9Very Negative

Cash Flow

14Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	742.00K	642.00K	2.27M	1.38M	375.00K	0
Gross Profit	336.00K	478.00K	123.00K	120.00K	355.00K	0
EBITDA	-53.41M	-52.61M	-44.16M	-165.42M	-157.22M	-106.59M
Net Income	-70.86M	-69.90M	-59.60M	-179.05M	-165.76M	-106.93M
Balance Sheet
Total Assets	28.80M	44.92M	38.34M	73.70M	205.85M	239.44M
Cash, Cash Equivalents and Short-Term Investments	12.84M	28.41M	29.85M	65.22M	193.72M	232.97M
Total Debt	104.45M	109.66M	102.95M	101.38M	94.16M	1.40M
Total Liabilities	144.26M	140.38M	131.44M	130.21M	129.08M	17.77M
Stockholders Equity	-115.46M	-95.46M	-93.10M	-56.51M	76.78M	221.67M
Cash Flow
Free Cash Flow	-50.90M	-57.62M	-72.03M	-155.03M	-135.48M	-82.60M
Operating Cash Flow	-50.90M	-57.62M	-72.03M	-155.01M	-135.34M	-82.15M
Investing Cash Flow	0	0	0	-20.00K	-139.00K	-445.00K
Financing Cash Flow	46.13M	56.52M	36.66M	26.52M	96.24M	102.45M

Bioxcel Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.12Negative

100DMA0.57Negative

200DMA0.98Negative

Market Momentum

MACD-0.04Negative

RSI30.45Neutral

STOCH16.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTAIQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.12, and below the 200-day MA of 0.98, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 30.45 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTAIQ.

Bioxcel Therapeutics Risk Analysis

Bioxcel Therapeutics disclosed 86 risk factors in its most recent earnings report. Bioxcel Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.If we do not complete a strategic transaction, or do not receive sufficient financing from other sources of equity or debt financings, we may be required to seek relief under the U.S. Bankruptcy Code. Even if we are successful in raising additional capital, we will require substantial additional financing to service our debt facilities and achieve our goals and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.Q2, 2026

2.We are substantially restricted in our corporate activities by our existing debt facilities and are considering all strategic alternatives. If we do not properly service and/or restructure our debt facilities or achieve an alternative strategic transaction, substantial doubt exists about our ability to continue as a going concern.Q2, 2026

Bioxcel Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BTAIQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATNM	60Neutral	$46.53M	4.11	83.42%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCAB	45Neutral	$3.50M	-0.07	89.25%	―	-22.73%	53.53%
IPSC	45Neutral	$266.18M	-1.41	-52.76%	―	-100.00%	-219.52%
ANVS	40Underperform	$48.23M	-0.63	-685.96%	―	―	11.96%
BTAIQ	38Underperform	$406.97K	-0.01	69.92%	―	-14.52%	66.63%

* Healthcare Sector Average

Performance Comparison

BTAIQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BTAIQ	Bioxcel Therapeutics	0.01	-1.89	-99.32%
ATNM	Actinium Pharmaceuticals	1.48	0.10	7.25%
ANVS	Annovis Bio Inc	1.13	-0.89	-44.06%
BCAB	Bioatla, Inc.	2.10	-31.12	-93.68%
IPSC	Century Therapeutics, Inc.	1.47	0.87	145.00%

Bioxcel Therapeutics Corporate Events

Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsM&A Transactions

BioXcel Therapeutics Transitions to BX Liquidation Vehicle

Negative

Oct 30, 2026

BioXcel Therapeutics, Inc., which sought Chapter 11 protection on August 27, 2026, has sold substantially all of its neuroscience assets to Teva Pharmaceuticals International GmbH following a court-approved bidding process in the U.S. Bankruptcy Cour...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Bioxcel Therapeutics AI Stock Analysis